HC Wainwright & Co. : Cybin (CYBN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
HC Wainwright & Co. : Cybin (CYBN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
HC Wainwright & Co. Reiterates Buy on Cybin, Maintains $5 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.
Cybin Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 1369.72% HC Wainwright & Co. → $5 Reiterates Buy → Buy 03/13/2024 1369.72% HC Wainwright & Co.
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate a Psilocybin Service Center.Oregon is the only state in
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next mon
Cybin Inc. Advances Psychedelic Treatments for Mental Health
Cybin Provides Corporate Update And Highlights Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In MDD Expected In Mid-2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Q4 2024
- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 -- Received U.S. Foo
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.
Psychedelic Drug Developers Could Benefit From NIH Funding for Chronic Pain
Cybin Inc. CEO to Speak at Milken Global Conference
Cybin to Participate at the 27th Annual Milken Institute Global Conference
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled "Collaborating for Improved Mental Health."
Cybin Inc. Unveils Promising Psychedelic Research
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
- Publication explores structure-activity relationships ("SAR") of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist
Cedar Clinical Research Selected as Clinical Research Site for Cybin's Phase 3 Study of CYB003
VANCOUVER, BC, April 17, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behaviora
Cybin Inc. Secures Patent, Progresses MDD Therapy
Cybin Announces Grant Of Additional US Patent In Support Of Its CYB003 Breakthrough Therapy Program For Major Depressive Disorder
Cybin Announces Grant Of Additional US Patent In Support Of Its CYB003 Breakthrough Therapy Program For Major Depressive Disorder
Cybin Announces Grant of Additional U.S. Patent in Support of Its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of its CYB003 program in Major Depressive Disorder ("MDD").
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.See previous edition Psychedelics Headlines: Substitution Survey, Fr
No Data